STI-1558

DRUG5 trials

Sponsors

Sorrento Therapeutics, Inc., Zhejiang ACEA Pharmaceutical Co. Ltd.

Conditions

COVID-19COVID-19 PneumoniaSARS-CoV-2 Infection

Phase 1

Study to Assess the Safety, Tolerability and Pharmacokinetics of STI-1558 in Healthy Volunteers

CompletedNCT05364840

Sorrento Therapeutics, Inc.COVID-19

Start: 2022-06-07End: 2022-11-04Updated: 2023-01-30

Safety and Efficacy Study of STI-1558 in Healthy Adults and SARS-CoV-2-Positive Patients

CompletedNCT05523739

Zhejiang ACEA Pharmaceutical Co. Ltd.SARS-CoV-2 Infection

Start: 2022-09-16End: 2023-03-29Updated: 2023-08-14

A Study to Evaluate the Relative Bioavailability of STI-1558 and the Effect of Itraconazole and Rifampin on the Pharmacokinetics of STI-1558

CompletedNCT05685719

Zhejiang ACEA Pharmaceutical Co. Ltd.COVID-19 Pneumonia

Start: 2023-01-04End: 2023-11-03Updated: 2023-12-07

A Bioequivalence Trial of Fasting Single Oral STI-1558 Capsule in Healthy Chinese Subjects

CompletedNCT06044233

Zhejiang ACEA Pharmaceutical Co. Ltd.COVID-19

Start: 2023-09-28End: 2023-11-08Updated: 2023-12-13

Phase 3

Study to Assess the Efficacy and Safety of STI-1558 in Adult Subjects With Mild or Moderate (COVID-19)

CompletedNCT05716425

Zhejiang ACEA Pharmaceutical Co. Ltd.COVID-19

Start: 2023-02-08End: 2023-07-26Updated: 2024-05-14

Related Papers

Olgotrelvir as a Single-Agent Treatment of Nonhospitalized Patients with Covid-19

NEJM Evidence2024-05-285 citations

Olgotrelvir, a dual inhibitor of SARS-CoV-2 M<sup>pro</sup> and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19.

2024-01-0427 citations